GENE ONLINE|News &
Opinion
Blog

Roche
Roche’s Phase III Trial of ES-SCLC Immunotherapy Fails to Extend Progression-Free Survival
2022-04-05
The Lancet Publishes Data on Roche’s Long-Lasting Bispecific Antibody for Vision Loss
2022-01-25
With A New Medical Device and Accompanying Platform, Roche Advances its Digital Ecosystem
2022-01-14
JPM22 Highlights: Amgen Sees Potential in Arrakis, Freenome Gets Boosted by Roche Again
2022-01-12
Roche Looks for Peptide-Like Small Molecules with Prism BioLab, joining Merck, Eisai and Boehringer Ingelheim
2022-01-05
Roche Gets Shareholders Nod to Repurchase $21B Equity Stake Held By Novartis
2021-11-27
FDA Approves Samsung Bioepis and Biogen’s Lucentis Biosimilar
2021-09-22
Roche to Acquire Long-Time Partner to Advance Molecular Diagnostics for Infectious Diseases
2021-09-10
Adaptimmune Therapeutics Breaks Rough Patch With New Multibillion-Dollar Collaboration
2021-09-08
Roche Bets on Shape’s RNA Editing Tech in $3B Gene Therapy Collab
2021-08-25
Roche Aspires for Dominance in DLBCL Market, Unveils Pivotal Trial Data for Polivy
2021-08-09
Japan’s SoftBank Buys $5 billion Stake in Roche, Becoming One of its Largest Investors
2021-08-05
WHO Recommends the Use of Sanofi’s and Roche’s Rheumatoid Arthritis Drugs to Cut COVID-19 Deaths
2021-07-12
Genentech Seeks FDA’s Blessings after Adjuvant Tecentriq Shows Promising Result in Lung Cancer Patients
2021-03-23
M&A
Roche Forays into Syndromic Panel Testing by Placing $1.8 Billion Bet on GenMark Acquisition
2021-03-15
1 2 3 4 6
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!